Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Wright State University

Summary

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

Eligibility

Age range: 18–50 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * Female and Male adult subjects age 18 to 50 * Must be able to give informed consent * Have access to stable transportation * All skin types on Fitzpatrick Scale (Type I-VI) * Self-Identified photosensitivity * Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer. Exclusion Criteria: * Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus) * Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories…

Interventions

Drug
4% Imipramine Cream
4% Imipramine Cream
Drug
Base Cream
Base Cream

Location

Wright State Physicians
Fairborn, Ohio